4.7 Article

Development and validation of an interpretable deep learning framework for Alzheimer's disease classification

Journal

BRAIN
Volume 143, Issue -, Pages 1920-1933

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/brain/awaa137

Keywords

dementia; biomarkers; Alzheimer's disease; structural MRI; neurodegeneration

Funding

  1. National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI Grant [1UL1TR001430]
  2. American Heart Association [17SDG33670323]
  3. Hariri Institute for Computing and Computational Science & Engineering at Boston University
  4. Framingham Heart Study's National Heart, Lung and Blood Institute [N01-HC-25195, HHSN268201500001I]
  5. NIH [R56-AG062109, AG008122, R01-AG016495, R01-AG033040]
  6. Boston University's Affinity Research Collaboratives program
  7. Boston University Alzheimer's Disease Center [P30-AG013846]

Ask authors/readers for more resources

Alzheimer's disease is the primary cause of dementia worldwide, with an increasing morbidity burden that may outstrip diagnosis and management capacity as the population ages. Current methods integrate patient history, neuropsychological testing and MRI to identify likely cases, yet effective practices remain variably applied and lacking in sensitivity and specificity. Here we report an interpretable deep learning strategy that delineates unique Alzheimer's disease signatures from multimodal inputs of MRI, age, gender, and Mini-Mental State Examination score. Our framework linked a fully convolutional network, which constructs high resolution maps of disease probability from local brain structure to a multilayer perceptron and generates precise, intuitive visualization of individual Alzheimer's disease risk en route to accurate diagnosis. The model was trained using clinically diagnosed Alzheimer's disease and cognitively normal subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset (n = 417) and validated on three independent cohorts: the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) (n = 382), the Framingham Heart Study (n = 102), and the National Alzheimer's Coordinating Center (NACC) (n = 582). Performance of the model that used the multimodal inputs was consistent across datasets, with mean area under curve values of 0.996, 0.974, 0.876 and 0.954 for the ADNI study, AIBL, Framingham Heart Study and NACC datasets, respectively. Moreover, our approach exceeded the diagnostic performance of a multi-institutional team of practicing neurologists (n = 11), and high-risk cerebral regions predicted by the model closely tracked post-mortem histopathological findings. This framework provides a clinically adaptable strategy for using routinely available imaging techniques such as MRI to generate nuanced neuroimaging signatures for Alzheimer's disease diagnosis, as well as a generalizable approach for linking deep learning to pathophysiological processes in human disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available